Publication outcomes of phase II oncology clinical trials

Rasmus Hoeg, Jennifer A. Lee, Michelle A. Mathiason, Kristina Rokkones, Stephanie L. Serck, Kaye L. Crampton, Ann E. Emmel, Eileen A. Severson, Ronald S. Go

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: Translation of evidence-based medicine into oncology practice depends on timely and full publication of clinical trials. We investigated publication outcomes of Phase II trial abstracts from the annual meetings of the American Society of Clinical Oncology (ASCO). Methods: We searched the 1997, 1999, and 2001 ASCO annual meeting proceedings and identified all Phase II trials, excluding those that reported preliminary results. Literature search was performed using PubMed, EMBASE, and Google for corresponding publications in peer-reviewed journals. We attempted to contact authors of all unpublished trials. Results: Only 60.8% of t he 559 trials identified were published, with a median time to publication of 41 months. At 5 years, 65.9%, 62.7%, and 57.0% of studies from 1997, 1999, and 2001, respectively, were published. Studies with larger samples were associated with a shorter time to publication, as were oral and poster presentations versus print only (P < 0.001). Common reasons for not publishing were uninteresting results, lack of time, and relocation of authors. Among abstracts reporting response rates, 37.7% showed different results in subsequent publications. Though not statistically significant, over the 5-year period, abstracts presented at later years had a lower rate of publication, longer time to publication, and a higher likelihood of showing a better tumor response. Conclusions: Almost half of Phase II trials presented at ASCO annual meetings within the last 10 years remain unpublished. Over one-third of published trials reported results different from those presented in abstracts. Like Phase I and III trials, Phase II trials often are unpublished.

Original languageEnglish (US)
Pages (from-to)253-257
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume32
Issue number3
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Phase II Clinical Trials
Publications
Medical Oncology
Posters
Evidence-Based Medicine
PubMed
Clinical Trials

Keywords

  • Oncology trials
  • Phase II
  • Publication outcome

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hoeg, R., Lee, J. A., Mathiason, M. A., Rokkones, K., Serck, S. L., Crampton, K. L., ... Go, R. S. (2009). Publication outcomes of phase II oncology clinical trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 32(3), 253-257. https://doi.org/10.1097/COC.0b013e3181845544

Publication outcomes of phase II oncology clinical trials. / Hoeg, Rasmus; Lee, Jennifer A.; Mathiason, Michelle A.; Rokkones, Kristina; Serck, Stephanie L.; Crampton, Kaye L.; Emmel, Ann E.; Severson, Eileen A.; Go, Ronald S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 32, No. 3, 01.06.2009, p. 253-257.

Research output: Contribution to journalArticle

Hoeg, R, Lee, JA, Mathiason, MA, Rokkones, K, Serck, SL, Crampton, KL, Emmel, AE, Severson, EA & Go, RS 2009, 'Publication outcomes of phase II oncology clinical trials', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 32, no. 3, pp. 253-257. https://doi.org/10.1097/COC.0b013e3181845544
Hoeg, Rasmus ; Lee, Jennifer A. ; Mathiason, Michelle A. ; Rokkones, Kristina ; Serck, Stephanie L. ; Crampton, Kaye L. ; Emmel, Ann E. ; Severson, Eileen A. ; Go, Ronald S. / Publication outcomes of phase II oncology clinical trials. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2009 ; Vol. 32, No. 3. pp. 253-257.
@article{fe27e4c373d9482e8addfa117f208a09,
title = "Publication outcomes of phase II oncology clinical trials",
abstract = "Objectives: Translation of evidence-based medicine into oncology practice depends on timely and full publication of clinical trials. We investigated publication outcomes of Phase II trial abstracts from the annual meetings of the American Society of Clinical Oncology (ASCO). Methods: We searched the 1997, 1999, and 2001 ASCO annual meeting proceedings and identified all Phase II trials, excluding those that reported preliminary results. Literature search was performed using PubMed, EMBASE, and Google for corresponding publications in peer-reviewed journals. We attempted to contact authors of all unpublished trials. Results: Only 60.8{\%} of t he 559 trials identified were published, with a median time to publication of 41 months. At 5 years, 65.9{\%}, 62.7{\%}, and 57.0{\%} of studies from 1997, 1999, and 2001, respectively, were published. Studies with larger samples were associated with a shorter time to publication, as were oral and poster presentations versus print only (P < 0.001). Common reasons for not publishing were uninteresting results, lack of time, and relocation of authors. Among abstracts reporting response rates, 37.7{\%} showed different results in subsequent publications. Though not statistically significant, over the 5-year period, abstracts presented at later years had a lower rate of publication, longer time to publication, and a higher likelihood of showing a better tumor response. Conclusions: Almost half of Phase II trials presented at ASCO annual meetings within the last 10 years remain unpublished. Over one-third of published trials reported results different from those presented in abstracts. Like Phase I and III trials, Phase II trials often are unpublished.",
keywords = "Oncology trials, Phase II, Publication outcome",
author = "Rasmus Hoeg and Lee, {Jennifer A.} and Mathiason, {Michelle A.} and Kristina Rokkones and Serck, {Stephanie L.} and Crampton, {Kaye L.} and Emmel, {Ann E.} and Severson, {Eileen A.} and Go, {Ronald S.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1097/COC.0b013e3181845544",
language = "English (US)",
volume = "32",
pages = "253--257",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Publication outcomes of phase II oncology clinical trials

AU - Hoeg, Rasmus

AU - Lee, Jennifer A.

AU - Mathiason, Michelle A.

AU - Rokkones, Kristina

AU - Serck, Stephanie L.

AU - Crampton, Kaye L.

AU - Emmel, Ann E.

AU - Severson, Eileen A.

AU - Go, Ronald S.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Objectives: Translation of evidence-based medicine into oncology practice depends on timely and full publication of clinical trials. We investigated publication outcomes of Phase II trial abstracts from the annual meetings of the American Society of Clinical Oncology (ASCO). Methods: We searched the 1997, 1999, and 2001 ASCO annual meeting proceedings and identified all Phase II trials, excluding those that reported preliminary results. Literature search was performed using PubMed, EMBASE, and Google for corresponding publications in peer-reviewed journals. We attempted to contact authors of all unpublished trials. Results: Only 60.8% of t he 559 trials identified were published, with a median time to publication of 41 months. At 5 years, 65.9%, 62.7%, and 57.0% of studies from 1997, 1999, and 2001, respectively, were published. Studies with larger samples were associated with a shorter time to publication, as were oral and poster presentations versus print only (P < 0.001). Common reasons for not publishing were uninteresting results, lack of time, and relocation of authors. Among abstracts reporting response rates, 37.7% showed different results in subsequent publications. Though not statistically significant, over the 5-year period, abstracts presented at later years had a lower rate of publication, longer time to publication, and a higher likelihood of showing a better tumor response. Conclusions: Almost half of Phase II trials presented at ASCO annual meetings within the last 10 years remain unpublished. Over one-third of published trials reported results different from those presented in abstracts. Like Phase I and III trials, Phase II trials often are unpublished.

AB - Objectives: Translation of evidence-based medicine into oncology practice depends on timely and full publication of clinical trials. We investigated publication outcomes of Phase II trial abstracts from the annual meetings of the American Society of Clinical Oncology (ASCO). Methods: We searched the 1997, 1999, and 2001 ASCO annual meeting proceedings and identified all Phase II trials, excluding those that reported preliminary results. Literature search was performed using PubMed, EMBASE, and Google for corresponding publications in peer-reviewed journals. We attempted to contact authors of all unpublished trials. Results: Only 60.8% of t he 559 trials identified were published, with a median time to publication of 41 months. At 5 years, 65.9%, 62.7%, and 57.0% of studies from 1997, 1999, and 2001, respectively, were published. Studies with larger samples were associated with a shorter time to publication, as were oral and poster presentations versus print only (P < 0.001). Common reasons for not publishing were uninteresting results, lack of time, and relocation of authors. Among abstracts reporting response rates, 37.7% showed different results in subsequent publications. Though not statistically significant, over the 5-year period, abstracts presented at later years had a lower rate of publication, longer time to publication, and a higher likelihood of showing a better tumor response. Conclusions: Almost half of Phase II trials presented at ASCO annual meetings within the last 10 years remain unpublished. Over one-third of published trials reported results different from those presented in abstracts. Like Phase I and III trials, Phase II trials often are unpublished.

KW - Oncology trials

KW - Phase II

KW - Publication outcome

UR - http://www.scopus.com/inward/record.url?scp=67749145692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67749145692&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181845544

DO - 10.1097/COC.0b013e3181845544

M3 - Article

C2 - 19349853

AN - SCOPUS:67749145692

VL - 32

SP - 253

EP - 257

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -